These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 7585594)
1. Design and analysis of in vitro antitumor pharmacodynamic studies. Kalns JE; Millenbaugh NJ; Wientjes MG; Au JL Cancer Res; 1995 Nov; 55(22):5315-22. PubMed ID: 7585594 [TBL] [Abstract][Full Text] [Related]
2. In vitro pharmacodynamic assay for cancer drug development: application to crisnatol, a new DNA intercalator. Adams DJ Cancer Res; 1989 Dec; 49(23):6615-20. PubMed ID: 2819712 [TBL] [Abstract][Full Text] [Related]
3. A pharmacodynamic analysis method to determine the relative importance of drug concentration and treatment time on effect. Millenbaugh NJ; Wientjes MG; Au JL Cancer Chemother Pharmacol; 2000; 45(4):265-72. PubMed ID: 10755313 [TBL] [Abstract][Full Text] [Related]
4. In vitro cell growth pharmacodynamic studies: a new nonparametric approach to determining the relative importance of drug concentration and treatment time. Germani M; Magni P; De Nicolao G; Poggesi I; Marsiglio A; Ballinari D; Rocchetti M Cancer Chemother Pharmacol; 2003 Dec; 52(6):507-13. PubMed ID: 12923660 [TBL] [Abstract][Full Text] [Related]
5. Modeling of the time-dependency of in vitro drug cytotoxicity and resistance. Levasseur LM; Slocum HK; Rustum YM; Greco WR Cancer Res; 1998 Dec; 58(24):5749-61. PubMed ID: 9865733 [TBL] [Abstract][Full Text] [Related]
6. Simultaneous versus sequential pharmacokinetic-pharmacodynamic population analysis using an iterative two-stage Bayesian technique. Proost JH; Schiere S; Eleveld DJ; Wierda JM Biopharm Drug Dispos; 2007 Nov; 28(8):455-73. PubMed ID: 17847121 [TBL] [Abstract][Full Text] [Related]
7. [Meta-analysis of the Italian studies on short-term effects of air pollution]. Biggeri A; Bellini P; Terracini B; Epidemiol Prev; 2001; 25(2 Suppl):1-71. PubMed ID: 11515188 [TBL] [Abstract][Full Text] [Related]
8. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity. Müller L; Gocke E; Lavé T; Pfister T Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141 [TBL] [Abstract][Full Text] [Related]
9. Effects of long-term exposure to traffic-related air pollution on respiratory and cardiovascular mortality in the Netherlands: the NLCS-AIR study. Brunekreef B; Beelen R; Hoek G; Schouten L; Bausch-Goldbohm S; Fischer P; Armstrong B; Hughes E; Jerrett M; van den Brandt P Res Rep Health Eff Inst; 2009 Mar; (139):5-71; discussion 73-89. PubMed ID: 19554969 [TBL] [Abstract][Full Text] [Related]
10. A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and -nonspecific drugs. Gardner SN Cancer Res; 2000 Mar; 60(5):1417-25. PubMed ID: 10728708 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Zhao L; Wientjes MG; Au JL Clin Cancer Res; 2004 Dec; 10(23):7994-8004. PubMed ID: 15585635 [TBL] [Abstract][Full Text] [Related]
12. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice. Marsman D Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194 [TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic parameter estimation: population size versus number of samples. Girgis S; Pai SM; Girgis IG; Batra VK AAPS J; 2005 Oct; 7(2):46. PubMed ID: 16353905 [TBL] [Abstract][Full Text] [Related]
14. Determining the error of dose estimates and minimum and maximum acceptable concentrations from assays with nonlinear dose-response curves. Gottschalk PG; Dunn JR Comput Methods Programs Biomed; 2005 Dec; 80(3):204-15. PubMed ID: 16256244 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic-pharmacodynamic model for educational simulations. van Meurs WL; Nikkelen E; Good ML IEEE Trans Biomed Eng; 1998 May; 45(5):582-90. PubMed ID: 9581056 [TBL] [Abstract][Full Text] [Related]
16. A model-based approach to the in vitro evaluation of anticancer activity. Del Bene F; Germani M; De Nicolao G; Magni P; Re CE; Ballinari D; Rocchetti M Cancer Chemother Pharmacol; 2009 Apr; 63(5):827-36. PubMed ID: 18663447 [TBL] [Abstract][Full Text] [Related]
17. Extended follow-up and spatial analysis of the American Cancer Society study linking particulate air pollution and mortality. Krewski D; Jerrett M; Burnett RT; Ma R; Hughes E; Shi Y; Turner MC; Pope CA; Thurston G; Calle EE; Thun MJ; Beckerman B; DeLuca P; Finkelstein N; Ito K; Moore DK; Newbold KB; Ramsay T; Ross Z; Shin H; Tempalski B Res Rep Health Eff Inst; 2009 May; (140):5-114; discussion 115-36. PubMed ID: 19627030 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of cell-killing effects of 1-beta-D-arabinofuranosylcytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system. Kishi S; Goto N; Nakamura T; Ueda T Cancer Res; 1999 Jun; 59(11):2629-34. PubMed ID: 10363985 [TBL] [Abstract][Full Text] [Related]
19. Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modelling. Gieschke R; Reigner BG; Steimer JL Int J Clin Pharmacol Ther; 1997 Oct; 35(10):469-74. PubMed ID: 9352398 [TBL] [Abstract][Full Text] [Related]
20. Electronic monitoring of variation in drug intakes can reduce bias and improve precision in pharmacokinetic/pharmacodynamic population studies. Vrijens B; Goetghebeur E Stat Med; 2004 Feb; 23(4):531-44. PubMed ID: 14755387 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]